Published in Nature on May 20, 2009
Causes and consequences of aneuploidy in cancer. Nat Rev Genet (2012) 4.08
NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol (2010) 2.77
NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer (2009) 2.18
Interaction of calcineurin with substrates and targeting proteins. Trends Cell Biol (2010) 1.84
DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev (2011) 1.82
Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep (2012) 1.81
Reprogramming cellular identity for regenerative medicine. Cell (2012) 1.71
Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature (2010) 1.70
The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep (2013) 1.61
The aneuploidy paradox: costs and benefits of an incorrect karyotype. Trends Genet (2011) 1.60
Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature (2010) 1.57
Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. Hum Mol Genet (2010) 1.54
Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep (2012) 1.51
Down's syndrome patients are less likely to develop cancer. Clin Genet (2010) 1.44
A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet (2010) 1.42
Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell (2012) 1.35
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest (2012) 1.29
Down syndrome: searching for the genetic culprits. Dis Model Mech (2011) 1.28
p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep (2011) 1.25
Induced pluripotent stem cells for modelling human diseases. Philos Trans R Soc Lond B Biol Sci (2011) 1.17
Massive-scale RNA-Seq analysis of non ribosomal transcriptome in human trisomy 21. PLoS One (2011) 1.15
Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med (2013) 1.11
Regulator of calcineurin 1 (RCAN1) facilitates neuronal apoptosis through caspase-3 activation. J Biol Chem (2011) 1.11
Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci (2013) 1.11
NFAT promotes carcinoma invasive migration through glypican-6. Biochem J (2011) 1.09
Upregulation of three Drosophila homologs of human chromosome 21 genes alters synaptic function: implications for Down syndrome. Proc Natl Acad Sci U S A (2009) 1.08
Aneuploidy and chromosomal instability in cancer: a jackpot to chaos. Cell Div (2015) 1.07
NFAT gene family in inflammation and cancer. Curr Mol Med (2013) 1.02
Convergent Evolution of Calcineurin Pathway Roles in Thermotolerance and Virulence in Candida glabrata. G3 (Bethesda) (2012) 1.02
Tumorigenesis in Down's syndrome: big lessons from a small chromosome. Nat Rev Cancer (2012) 1.01
Emerging roles of store-operated Ca²⁺ entry through STIM and ORAI proteins in immunity, hemostasis and cancer. Channels (Austin) (2013) 1.00
The CCAAT/enhancer binding protein beta (C/EBPbeta) cooperates with NFAT to control expression of the calcineurin regulatory protein RCAN1-4. J Biol Chem (2010) 1.00
Impairment of circulating endothelial progenitors in Down syndrome. BMC Med Genomics (2010) 0.99
Neurological phenotypes for Down syndrome across the life span. Prog Brain Res (2012) 0.98
Integrative genomics identifies DSCR1 (RCAN1) as a novel NFAT-dependent mediator of phenotypic modulation in vascular smooth muscle cells. Hum Mol Genet (2009) 0.97
Mouse models for Down syndrome-associated developmental cognitive disabilities. Dev Neurosci (2011) 0.95
Do RCAN1 proteins link chronic stress with neurodegeneration? FASEB J (2011) 0.95
Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle. Mol Cell (2013) 0.95
Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About? Curr Genomics (2010) 0.94
Increased survival following tumorigenesis in Ts65Dn mice that model Down syndrome. Cancer Res (2011) 0.93
Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes. Dev Neurosci (2011) 0.92
Kaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLCγ1 and activating NFAT1-dependent RCAN1 expression. PLoS Pathog (2012) 0.91
Chronic expression of RCAN1-1L protein induces mitochondrial autophagy and metabolic shift from oxidative phosphorylation to glycolysis in neuronal cells. J Biol Chem (2012) 0.91
NFAT as cancer target: mission possible? Biochim Biophys Acta (2014) 0.91
Regulator of calcineurin 1 mediates pathological vascular wall remodeling. J Exp Med (2011) 0.90
Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid (2011) 0.90
Behavioral characterization of a mouse model overexpressing DSCR1/ RCAN1. PLoS One (2011) 0.89
Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A (2012) 0.89
Low risk of solid tumors in persons with Down syndrome. Genet Med (2016) 0.88
Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer (2013) 0.88
Putting stem cells to the test. Nat Med (2010) 0.88
Patient-specific pluripotent stem cells in neurological diseases. Stem Cells Int (2011) 0.88
VEGF stimulates RCAN1.4 expression in endothelial cells via a pathway requiring Ca2+/calcineurin and protein kinase C-delta. PLoS One (2010) 0.87
Survival and morbidity outcomes for very low birth weight infants with Down syndrome. Pediatrics (2010) 0.87
A mouse embryonic stem cell bank for inducible overexpression of human chromosome 21 genes. Genome Biol (2010) 0.86
Antioxidants in Down syndrome. Biochim Biophys Acta (2011) 0.85
RCAN1 overexpression exacerbates calcium overloading-induced neuronal apoptosis. PLoS One (2014) 0.84
Chronic high levels of the RCAN1-1 protein may promote neurodegeneration and Alzheimer disease. Free Radic Biol Med (2013) 0.84
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Front Pharmacol (2014) 0.83
The Robyn Barst Memorial Lecture: Differences between the fetal, newborn, and adult pulmonary circulations: relevance for age-specific therapies (2013 Grover Conference series). Pulm Circ (2014) 0.83
NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect. PLoS One (2013) 0.83
From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome. Neural Plast (2012) 0.82
NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol (2015) 0.82
The calcineurin-NFAT pathway negatively regulates megakaryopoiesis. Blood (2013) 0.81
Determining frequent patterns of copy number alterations in cancer. PLoS One (2010) 0.81
CXM: a new tool for mapping breast cancer risk in the tumor microenvironment. Cancer Res (2014) 0.81
Genetic dissection of Down syndrome-associated congenital heart defects using a new mouse mapping panel. Elife (2016) 0.80
A major role for RCAN1 in atherosclerosis progression. EMBO Mol Med (2013) 0.80
DYRK1A in Down syndrome: an oncogene or tumor suppressor? J Clin Invest (2012) 0.80
Concise review: new paradigms for Down syndrome research using induced pluripotent stem cells: tackling complex human genetic disease. Stem Cells Transl Med (2013) 0.80
Aneuploid proliferation defects in yeast are not driven by copy number changes of a few dosage-sensitive genes. Genes Dev (2015) 0.80
Stem and progenitor cell dysfunction in human trisomies. EMBO Rep (2014) 0.79
Herpesviral G protein-coupled receptors activate NFAT to induce tumor formation via inhibiting the SERCA calcium ATPase. PLoS Pathog (2015) 0.79
The vertebrate RCAN gene family: novel insights into evolution, structure and regulation. PLoS One (2014) 0.79
The RCAN1 inhibits NF-κB and suppresses lymphoma growth in mice. Cell Death Dis (2015) 0.79
Aurea mediocritas: the importance of a balanced genome. Cold Spring Harb Perspect Biol (2014) 0.79
Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1). Mamm Genome (2012) 0.79
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis. Mol Cell Oncol (2015) 0.79
Transcriptome analysis of the spalax hypoxia survival response includes suppression of apoptosis and tight control of angiogenesis. BMC Genomics (2012) 0.78
Trisomic and allelic differences influence phenotypic variability during development of Down syndrome mice. Genetics (2011) 0.78
The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. Leukemia (2016) 0.78
Over-expression of DSCR1 protects against post-ischemic neuronal injury. PLoS One (2012) 0.77
Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer. Pharmacogenet Genomics (2015) 0.77
RCAN1 links impaired neurotrophin trafficking to aberrant development of the sympathetic nervous system in Down syndrome. Nat Commun (2015) 0.77
The use of mouse models for understanding the biology of down syndrome and aging. Curr Gerontol Geriatr Res (2012) 0.77
Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21. J Biomed Res (2010) 0.76
Generation and applications of human pluripotent stem cells induced into neural lineages and neural tissues. Front Physiol (2012) 0.76
Increased Lung Expression of Anti-Angiogenic Factors in Down Syndrome: Potential Role in Abnormal Lung Vascular Growth and the Risk for Pulmonary Hypertension. PLoS One (2016) 0.75
Combined obstructive hypertrophic cardiomyopathy and double outlet right ventricle in an infant with Down syndrome. Am J Case Rep (2013) 0.75
Increased Skin Tumor Incidence and Keratinocyte Hyper-Proliferation in a Mouse Model of Down Syndrome. PLoS One (2016) 0.75
The regulator of calcineurin (RCAN1) an important factor involved in atherosclerosis and cardiovascular diseases development. J Med Life (2015) 0.75
Human induced pluripotent stem cells labeled with fluorescent magnetic nanoparticles for targeted imaging and hyperthermia therapy for gastric cancer. Cancer Biol Med (2015) 0.75
Synaptic Vesicle Recycling Is Unaffected in the Ts65Dn Mouse Model of Down Syndrome. PLoS One (2016) 0.75
RCAN1-4 is a thyroid cancer growth and metastasis suppressor. JCI Insight (2017) 0.75
Mouse-based genetic modeling and analysis of Down syndrome. Br Med Bull (2016) 0.75
Cyclosporin A promotes tumor angiogenesis in a calcineurin-independent manner by increasing mitochondrial reactive oxygen species. Mol Cancer Res (2014) 0.75
Modulation of VEGF receptor 2 signaling by protein phosphatases. Pharmacol Res (2016) 0.75
Angiogenesis: Reducing risk. Nat Rev Cancer (2010) 0.75
Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP. Front Behav Neurosci (2015) 0.75
Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy. Oncotarget (2016) 0.75
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell (1991) 15.76
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 9.18
A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet (1995) 4.95
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature (2006) 4.80
A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science (2004) 4.16
Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet (2000) 3.84
A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature (2006) 3.61
Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res (2008) 3.50
Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet (2002) 3.35
Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med (1993) 3.21
Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res (2000) 3.04
Single-copy transgenic mice with chosen-site integration. Proc Natl Acad Sci U S A (1996) 2.84
Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature (2008) 2.71
Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med (2001) 2.22
The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nat Immunol (2003) 2.17
Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Biol Chem (2004) 2.05
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell (2008) 1.72
Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene. Genomics (1997) 1.68
Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood (2004) 1.62
Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med (2005) 1.55
Down's syndrome: an atheroma-free model? Br Med J (1977) 1.50
Down syndrome candidate region 1,a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J Vasc Res (2004) 1.20
Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int J Cancer (2006) 1.19
VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis? Biochem Biophys Res Commun (2004) 1.12
A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res (1998) 1.07
Elevated expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in cerebellar unipolar brush cells of a Down syndrome mouse model. Cell Mol Neurobiol (2006) 1.05
The mapping of transgenes by fluorescence in situ hybridization on G-banded mouse chromosomes. Mamm Genome (1994) 0.95
Diabetic retinopathy in Down's syndrome. Br J Ophthalmol (1998) 0.92
Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2007) 30.84
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Selective blockade of microRNA processing by Lin28. Science (2008) 14.39
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol (2009) 11.18
Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet (2009) 10.54
Somatic coding mutations in human induced pluripotent stem cells. Nature (2011) 9.50
Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell (2009) 8.97
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol (2009) 7.59
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature (2011) 7.43
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell (2011) 7.41
Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol (2009) 6.76
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature (2010) 6.06
HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell (2002) 5.71
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet (2010) 5.37
The promise of induced pluripotent stem cells in research and therapy. Nature (2012) 5.05
Regulatory networks define phenotypic classes of human stem cell lines. Nature (2008) 4.98
Generation of induced pluripotent stem cells from human blood. Blood (2009) 4.92
Generation of human-induced pluripotent stem cells. Nat Protoc (2008) 4.85
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell (2009) 4.69
The Lin28/let-7 axis regulates glucose metabolism. Cell (2011) 4.65
Derivation of embryonic germ cells and male gametes from embryonic stem cells. Nature (2003) 4.56
Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell (2002) 4.56
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem (2008) 4.40
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature (2009) 4.14
Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol (2011) 3.97
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst (2002) 3.77
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res (2007) 3.53
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Lin28: A microRNA regulator with a macro role. Cell (2010) 3.39
Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood (2007) 3.38
Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology (2010) 3.36
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol (2011) 3.25
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 3.10
Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A (2003) 3.10
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell (2010) 3.08
Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell (2013) 3.08
The terminology of teratocarcinomas and teratomas. Nat Biotechnol (2007) 3.03
Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell (2009) 3.03
Biomechanical forces promote embryonic haematopoiesis. Nature (2009) 2.99
Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science (2012) 2.98
Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell (2011) 2.98
Reprogramming of T cells from human peripheral blood. Cell Stem Cell (2010) 2.93
A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature (2009) 2.88
Transplantation of adult mouse iPS cell-derived photoreceptor precursors restores retinal structure and function in degenerative mice. PLoS One (2011) 2.86
Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation (2009) 2.86
Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg (2012) 2.85
Stage-specific signaling through TGFβ family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development (2011) 2.82
A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells. PLoS Genet (2009) 2.78
High-efficiency RNA interference in human embryonic stem cells. Stem Cells (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet (2010) 2.72
Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol (2011) 2.65
New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell (2008) 2.61
Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells (2009) 2.59
Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov (2011) 2.58
Teratoma formation assays with human embryonic stem cells: a rationale for one type of human-animal chimera. Cell Stem Cell (2007) 2.56
Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell (2011) 2.53
The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem (2003) 2.51
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells (2004) 2.37
The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci U S A (2009) 2.36